Serum immune checkpoint biomarkers as predictors of response to anti-PD-1/PD-L1 treatment in non-small cell lung cancer (NSCLC) patients

被引：0
|
作者：
Raza, A. [1 ]
Mohsin, R. [1 ]
Kanbour, A. [1 ]
Vijayakar, S. [1 ]
Philip, A. [1 ]
Tauro, M. A. [1 ]
Sherif, S. [1 ]
Merhi, M. [1 ]
Inchakalody, V. [1 ]
Gul, A. R. Zar [1 ]
Al Homsi, M. U. [1 ]
Dermime, S. [1 ]
机构：
[1] Al Amal Hosp, Natl Ctr Canc Care & Res, Hamad Med Corp HMC, Dept Med Oncol, Ad Dawhah, Qatar
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15P
引用
收藏
页码：S1380 / S1380
页数：1
相关论文
共 50 条
  • [1] Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
    Raza, Afsheen
    Mohsen, Reyad
    Kanbour, Aladdin
    Gul, Abdul Rehman Zar
    Philip, Anite
    Vijayakumar, Suma
    Hydrose, Shereena
    Prabhu, Kirti S.
    Al-Suwaidi, Aisha Khamis
    Inchakalody, Varghese Philipose
    Merhi, Maysaloun
    El-Ella, Dina Abo M.
    Tauro, Melissa Annrose
    Akbar, Shayista
    Al-Bozom, Issam
    Abualainin, Wafa
    Al-Abdulla, Rajaa
    Abu Sirriya, Shaza
    Hassnad, Suparna
    Uddin, Shahab
    Ibrahim, Mohamed Izham Mohamed
    Al Homsi, Ussama
    Demime, Said
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [2] Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer
    Shien, Kazuhiko
    Papadimitrakopoulou, Vassiliki A.
    Wistuba, Ignacio I.
    [J]. LUNG CANCER, 2016, 99 : 79 - 87
  • [3] Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
    Zeng, Tian
    Qin, Qin
    Bian, Zhiheng
    Li, Jianjun
    [J]. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) : 4194 - 4201
  • [4] Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC)
    Shah, Shalin
    Wood, Kevin
    Brisson, Ryan
    Karrison, Theodore
    Hensing, Thomas
    Luke, Jason J.
    Patel, Jyoti D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S310 - S310
  • [5] Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
    Shimada, Yoshihisa
    Matsubayashi, Jun
    Kudo, Yujin
    Maehara, Sachio
    Takeuchi, Susumu
    Hagiwara, Masaru
    Kakihana, Masatoshi
    Ohira, Tatsuo
    Nagao, Toshitaka
    Ikeda, Norihiko
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [6] Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
    Cabezon-Gutierrez, Luis
    Custodio-Cabello, Sara
    Palka-Kotlowska, Magda
    Alonso-Viteri, Soledad
    Khosravi-Shahi, Parham
    [J]. CLINICAL LUNG CANCER, 2021, 22 (05) : 381 - 389
  • [7] Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
    Yoshihisa Shimada
    Jun Matsubayashi
    Yujin Kudo
    Sachio Maehara
    Susumu Takeuchi
    Masaru Hagiwara
    Masatoshi Kakihana
    Tatsuo Ohira
    Toshitaka Nagao
    Norihiko Ikeda
    [J]. Scientific Reports, 11
  • [8] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [9] Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
    Su, Chaoyue
    Wang, Hui
    Liu, Yunru
    Guo, Qiaoru
    Zhang, Lingling
    Li, Jiajun
    Zhou, Wenmin
    Yan, Yanyan
    Zhou, Xinke
    Zhang, Jianye
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [10] Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
    Valecha, Gautam Kishore
    Vennepureddy, Adarsh
    Ibrahim, Uroosa
    Safa, Firas
    Samra, Bachar
    Atallah, Jean Paul
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (01) : 47 - 59
12345